Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology

Roy Altman, Bill Bosch, Kay Brune, Paola Patrignani, Clarence Young, Roy Altman, Bill Bosch, Kay Brune, Paola Patrignani, Clarence Young

Abstract

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class with anti-inflammatory, analgesic, and antipyretic properties. Contrary to the action of many traditional NSAIDs, diclofenac inhibits cyclooxygenase (COX)-2 enzyme with greater potency than it does COX-1. Similar to other NSAIDs, diclofenac is associated with serious dose-dependent gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, a number of different diclofenac-containing drug products have been developed with the goal of improving efficacy, tolerability, and patient convenience. Delayed- and extended-release forms of diclofenac sodium were initially developed with the goal of improving the safety profile of diclofenac and providing convenient, once-daily dosing for the treatment of patients with chronic pain. New drug products consisting of diclofenac potassium salt were associated with faster absorption and rapid onset of pain relief. These include diclofenac potassium immediate-release tablets, diclofenac potassium liquid-filled soft gel capsules, and diclofenac potassium powder for oral solution. The advent of topical formulations of diclofenac enabled local treatment of pain and inflammation while minimizing systemic absorption of diclofenac. SoluMatrix diclofenac, consisting of submicron particles of diclofenac free acid and a proprietary combination of excipients, was developed to provide analgesic efficacy at reduced doses associated with lower systemic absorption. This review illustrates how pharmaceutical technology has been used to modify the pharmacokinetic properties of diclofenac, leading to the creation of novel drug products with improved clinical utility.

Figures

Fig. 1
Fig. 1
Chemical structure of diclofenac drug products

References

    1. Langner M, Kozubek A. Pharmacokinetic modulation with particulate drug formulations. In: Mozafari MR, editor. Nanocarrier technologies. Netherlands: Springer; 2006. pp. 113–138.
    1. Carlson TJ, Fisher MB. Recent advances in high throughput screening for ADME properties. Comb Chem High Throughput Screen. 2008;11(3):258–264.
    1. Bernardo PH, Tong JC. In silico design of small molecules. Methods Mol Biol. 2012;800:25–31.
    1. Kodadek T. The rise, fall and reinvention of combinatorial chemistry. Chem Commun. 2011;47(35):9757–9763.
    1. Jones HM, Mayawala K, Poulin P. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J. 2013;15(2):377–387.
    1. Payeli SK, Latini R, Gebhard C, Patrignani A, Wagner U, Luscher TF, et al. Prothrombotic gene expression profile in vascular smooth muscle cells of human saphenous vein, but not internal mammary artery. Arterioscler Thromb Vasc Biol. 2008;28(4):705–710.
    1. Sun Z, Ya N, Adams RC, Fang FS. Particle size specifications for solid oral dosage forms: a regulatory perspective. Am Pharm Rev. 2010;13(4):70–73.
    1. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32(3 Suppl 1):33–42.
    1. Coxib and traditional NSAID Trialists’ (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.
    1. Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19(7):745–751.
    1. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320–326.
    1. Riera-Guardia N, Castellsague J, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, et al. The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointestinal complications. Meta-analysis of epidemiological studies. In: International conference on pharmacoepidemiology. Brighton; 2010.
    1. Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89(6):855–866.
    1. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388.
    1. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
    1. Briefing Documents for FDA Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSARM). Iroko Pharmaceuticals, LLC: Silver Spring; 2014.
    1. Novartis. About Novartis. Available from: . Accessed 10 Dec 2014.
    1. Lesney MS. Three paths to Novartis. Mod Drug Discov. 2004;7:19–20.
    1. Administration UFaD. Briefing Documents for FDA Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSARM). Novartis, FDA Advisory Committee Briefing Document; 2013.
    1. Todd PA, Sorkin EM. Diclofenac sodium. Drugs. 1988;35(3):244–285.
    1. Derry P, Derry S, Moore RA, McQuay HJ. Single dose oral diclofenac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;2:CD004768.
    1. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s.
    1. Maclagan T. The treatment of rheumatism by salicin and salicylic acid. BMJ. 1876;1(803):627.
    1. Stricker F. Ueber die Resultate der Behandlung der Polytharthritis rheumatica mit Salicylsaure. Berl Klin Wochenschr. 1876;13(1–2):15–16.
    1. Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321(7276):1591–1594.
    1. Brune K, Hinz B. The discovery and development of antiinflammatory drugs. Arthritis Rheum. 2004;50(8):2391–2399.
    1. Domenjoz R. The pharmacology of phenylbutazone analogues. Ann N Y Acad Sci. 1960;86(1):263–291.
    1. Voltaren Enteric Coated Tablets Prescribing Information. 2011 [updated February 2011]. Available from: . Accessed 27 Dec 2013.
    1. Cataflam Prescribing Information. 2009. Available from: . Accessed 5 Dec 2014.
    1. Voltaren XR Prescribing Information. 2009. Available from: . Accessed 27 Dec 2013.
    1. ARTHROTEC medical guide. NY; 2013. Available from: . Accessed 20 Feb 2014.
    1. Solaraze Prescribing Information. Parsippany; 2009. Available from: . Accessed 5 Jan 2014.
    1. Flector Prescribing Information. 2011 [updated February 2011]. Available from: .
    1. Voltaren Gel 1 % Prescribing Information. 2009 [updated October 2009]. Available from: . Accessed 1 Nov 2013.
    1. Cambia Prescribing Information. 2009. Available from: . Accessed 18 Nov 2013.
    1. Zipsor Full Prescribing Information. Newark; 2012. Available from: . Accessed 18 Nov 2013.
    1. Pennsaid Prescribing Information. 2009. Available from: . Accessed 27 Dec 2013.
    1. Pennsaid Prescribing Information. 2014. Available from: . Accessed 5 Dec 2014.
    1. Zorvolex Full Prescribing Information. 2013. Available from: . Accessed 8 Nov 2014.
    1. Highlights of Prescribing Information: Dyloject. Lake Forest: Hospira, Inc.; 1998 [updated 12/20141; cited 2015 March 17]; Available from: .
    1. Kuzell WC, Schaffarzick RW. Phenylbutazone (butazolidin) and butapyrin; a study of clinical effects in arthritis and gout. Calif Med. 1952;77(5):319–325.
    1. Shen TY, Windholz TB, Rosegay A, Witzel BE, Wilson AN, Willett JD, et al. Non-steroid anti-inflammatory agents. J Am Chem Soc. 1963;85(4):488–489.
    1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat N Biol. 1971;231(25):232–235.
    1. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediat Inflamm. 2013;2013:258209.
    1. Brune K. How aspirin might work: a pharmacokinetic approach. Agents Actions. 1974;4(4):230–232.
    1. Sallmann AR. The history of diclofenac. Am J Med. 1986;80(4B):29–33.
    1. Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin. 2008;24(10):2967–2992.
    1. Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80(4B):18–23.
    1. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108(1):7–13.
    1. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50(Suppl):S423–S428.
    1. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15.
    1. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271(3):1705–1712.
    1. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3–4):317–327.
    1. Huntjens D, Danhof M, Della Pasqua O. Pharmacokinetic–pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology. 2005;44(7):846–859.
    1. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–1636.
    1. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci. 1999;96(13):7563–7568.
    1. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245(5 Pt 1):G601–G623.
    1. Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4(5):605–621.
    1. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312(7046):1563–1566.
    1. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8905):1075–1078.
    1. Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–420.
    1. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129(8):907–916.
    1. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4(132):132ra54.
    1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308.
    1. Dai Y, Ge J. Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis. 2012;2012:245037.
    1. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–1817.
    1. Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80(3):264–274.
    1. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295–1301.
    1. Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63(3):850–859.
    1. Patrignani P, Tacconelli S, Piazuelo E, Di Francesco L, Dovizio M, Sostres C, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12(8):1320–1330.
    1. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997;33(3):184–213.
    1. Riess W, Stierlin H, Degen P, Faigle JW, Gerardin A, Moppert J, et al. Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol Suppl. 1978;22:17–29.
    1. Macia MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther. 1995;33(6):333–339.
    1. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther. 2000;38(11):546–551.
    1. Riad LE, Sawchuk RJ, McAlary MM, Chan KK. Effect of food on the multiple-peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am J Ther. 1995;2(4):237–242.
    1. Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittel-Forschung. 2001;51(11):885–890.
    1. Hinz B, Hug AM, Fotopoulos G, Gold MS. Bioequivalence study of low-dose diclofenac potassium tablet formulations. Int J Clin Pharmacol Ther. 2009;47(10):643–648.
    1. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124(2):288–292.
    1. John VA. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehabil. 1979;Suppl 2:22–37.
    1. Aylward M, Fowler PD, John V, Maddock J, Seldrup J. The influence of diclofenac sodium (Voltarol) on free, protein-bound and total plasma L-tryptophan in adult healthy male subjects. Rheumatol Rehabil. 1979;Suppl 2:47–59.
    1. Chuasuwan B, Binjesoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, et al. Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci. 2009;98(4):1206–1219.
    1. Lotsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, et al. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. Pharm Res. 2000;17(1):77–84.
    1. Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol. 1983;25(3):389–394.
    1. Brune K, Renner B, Hinz B. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol. 2010;10:589–598.
    1. Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology (Oxford). 2007;46(6):911–919.
    1. Fowler PD, Dawes PT, John VA, Shotton PA. Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol. 1986;31(4):469–472.
    1. Seppala E, Nissila M, Isomaki H, Nuotio P, Nykanen E, Laitinen O, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol. 1985;4(3):315–320.
    1. Cataflam, Voltaren and Voltaren-XR Prescribing Information. 2000. Available from: . Accessed 6 Aug 2014.
    1. Sacerdote P, Carrabba M, Galante A, Pisati R, Manfredi B, Panerai AE. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen. Inflamm Res. 1995;44(11):486–490.
    1. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol. 1979;16(6):405–410.
    1. Kendall MJ, Thornhill DP, Willis JV. Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol) Rheumatol Rehabil. 1979;Suppl 2:38–46.
    1. McCormack PL, Scott LJ. Diclofenac sodium injection (Dyloject): in postoperative pain. Drugs. 2008;68(1):123–130.
    1. Goh CF, Lane ME. Formulation of diclofenac for dermal delivery. Int J Pharm. 2014;473(1–2):607–616.
    1. Singh DH, Roychowdhury S, Verma P, Bhandari V. A review on recent advances of enteric coating. IOSR J Pharm. 2012;2(6):5–11.
    1. Schumacher HR., Jr Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis. J Clin Rheumatol. 2004;10(3 Suppl):S18–S25.
    1. Abrams GJ, Solomon L, Meyers OL. A long-term study of diclophenac sodium in the treatment of rheumatoid arthritis and osteo-arthrosis. S Afr Med J. 1978;53(12):442–445.
    1. Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin. 2012;28(1):163–178.
    1. Germain BF. A placebo-eontrolled study of diclofenac sodium for the treatment of osteoarthritis of the hip and knee. Curr Ther Res Clin Exp. 1985;37:259–268.
    1. Barnes CG, Berry H, Carter ME, Downie WW, Fowler PD, Moll JM, et al. Diclofenac sodium (Voltarol) and indomethacin: a multicentre comparative study in rheumatoid arthritis and osteoarthritis. Rheumatol Rehabil. 1979;Suppl 2:135–143.
    1. Seda H, Cardozo PC. Efficacy and tolerability of diclofenac sodium vs ibuprofen in osteoarthritis. Folha Medica. 1976;72:633–636.
    1. Geis GS. Efficacy and upper GI safety of diclofenac/misoprostol, piroxicam and naproxen in patients with osteoarthritis. Drugs. 1993;45(Suppl 1):15.
    1. Vetter G. A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients. Br J Clin Pract. 1985;39(7):276–281.
    1. Huntwork JC. Efficacy and safety of diclofenac compared with aspirin in the treatment of rheumatoid arthritis. Curr Ther Res Clin Exp. 1986;40:576–586.
    1. Caldwell JR. Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. Am J Med. 1986;80(4B):43–47.
    1. Osnes M, Larsen S, Eidsaunet W, Thom E. Effect of diclofenac and naproxen on gastroduodenal mucosa. Clin Pharmacol Ther. 1979;26(3):399–405.
    1. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov. 2005;4(5):381–385.
    1. Bravo SA, Lamas MC, Salomon CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharm Sci. 2002;5(3):213–219.
    1. Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26(7):1715–1731.
    1. Mascher H. The pharmacokinetics of a new sustained-release form of diclofenac sodium in humans. Drug Des Deliv. 1989;4(4):303–311.
    1. Su SF, Chou CH, Kung CF, Huang JD. In vitro and in vivo comparison of two diclofenac sodium sustained release oral formulations. Int J Pharm. 2003;260(1):39–46.
    1. Magosso E, Yuen KH, Choy WP, Ling SS, Ng BH, Ur-Rahman N, et al. Comparative bioavailability study of a generic sustained release diclofenac sodium tablet. Med J Malaysia. 2004;59(3):352–356.
    1. Lissy M, Scallion R, Stiff DD, Moore K. Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. Expert Opin Pharmacother. 2010;11(5):701–708.
    1. Marzo A, Dal Bo L, Verga F, Ceppi Monti N, Abbondati G, Tettamanti RA, et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittel-Forschung. 2000;50(1):43–47.
    1. Manvelian G, Daniels S, Gibofsky A. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac. Postgrad Med. 2012;124(1):117–123.
    1. Lissy M, Stiff DD, Kowalski MM, Moore KA. Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers. Curr Med Res Opin. 2009;25(10):2423–2428.
    1. Desjardins P, Olugemo K, Solorio D, Young C. The pharmacokinetics and safety of low-dose SoluMatrix® diclofenac. Clin Ther. 2015;37(2):448–461.
    1. Garbacz G, Wedemeyer RS, Nagel S, Giessmann T, Monnikes H, Wilson CG, et al. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses. Eur J Pharm Biopharm. 2008;70(2):421–428.
    1. Scott DL, Palmer RH. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther. 2000;14(4):443–452.
    1. Chopra A, Bichile L, Rayadhyaksha AG, Gadgil S, Maroli S, Goregaonkar AB, et al. Randomized double-blind clinical drug trials of meloxicam in rheumatoid arthritis and osteoarthritis knees: an Indian experience. APLAR J Rheumatol. 2004;7(2):108–116.
    1. Beaulieu AD, Peloso PM, Haraoui B, Bensen W, Thomson G, Wade J, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag. 2008;13(2):103–110.
    1. Le Loet X, Dreiser RL, Le Gros V, Febvre N. Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful osteoarthritis. Int J Clin Pract. 1997;51(6):389–393.
    1. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):30S–34S.
    1. ARTHROTEC medical guide. In: Diclofenac sodium/misoprostol tablets. NY; 2013. . Accessed 20 Feb 2014.
    1. Geis GS, Stead H, Wallemark CB, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl. 1991;28:11–14.
    1. Karim A, Smith M. Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec. Scand J Rheumatol Suppl. 1992;96:37–48.
    1. Altman R, Daniels S, Young CL. Indomethacin submicron particle capsules provide effective pain relief in patients with acute pain: a phase 3 study. Phys Sportsmed. 2013;41(4):7–15.
    1. de Melo Gomes JA. The safety of Arthrotec in patients with rheumatoid arthritis or osteoarthritis: an assessment of the upper gastrointestinal tract by endoscopy. Scand J Rheumatol Suppl. 1992;96:23–31.
    1. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol. 1998;25(8):1602–1611.
    1. Agrawal NM, Caldwell J, Kivitz AJ, Weaver AL, Bocanegra TS, Ball J, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther. 1999;21(4):659–674.
    1. Raskin JB, White RH, Jackson JE, Weaver AL, Tindall EA, Lies RB, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123(5):344–350.
    1. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–249.
    1. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2000;4:CD002296.
    1. Andersson T, Bredberg E, Lagerstrom PO, Naesdal J, Wilson I. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol. 1998;54(5):399–404.
    1. Sugano K, Kinoshita Y, Miwa H, Takeuchi T, Esomeprazole NSAID Preventive Study Group Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. BMC Gastroenterol. 2013;13:54.
    1. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–179.
    1. Massimo Claar G, Monaco S, Del Veccho Blanco C, Capurso L, Fusillo M, Annibale B. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 1998;12(5):463–468.
    1. The Nonsteroidal Anti-Inflammatory Drugs: Treating Osteoarthritis and Pain Comparing Effectiveness, Safety, and Price 2013. Available from: . Accessed 24 Mar 2014.
    1. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19(12):1861–1876.
    1. Moore N. Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig. 2007;27(3):163–195.
    1. Boghdady W, Lotfy M, William E. Diclofenac potassium in the management of dental pain: a multicenter double-blind comparison with glafenine. Egypt Dent J. 1993;39(3):461–466.
    1. Bahamonde LA, Saavedra H. Comparison of the analgesic and anti-inflammatory effects of diclofenac potassium versus piroxicam versus placebo in ankle sprain patients. J Int Med Res. 1990;18(2):104–111.
    1. Moran M. An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprains. Curr Med Res Opin. 1990;12(4):268–274.
    1. Moran M. Double-blind comparison of diclofenac potassium, ibuprofen and placebo in the treatment of ankle sprains. J Int Med Res. 1991;19(2):121–130.
    1. Olson NZ, Sunshine A, Zighelboim I, DeCastro A. Onset and duration of analgesia of diclofenac potassium in the treatment of postepisiotomy pain. Am J Ther. 1997;4(7–8):239–246.
    1. Chantler I, Mitchell D, Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain. 2008;24(1):39–44.
    1. Diamond S. Strategies for migraine management. Cleve Clin J Med. 1991;58(3):257–261.
    1. Group TD-KSMS Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia. 1999;19(4):232–240.
    1. Dahlof C, Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993;13(2):117–123.
    1. Diener HC, Montagna P, Gacs G, Lyczak P, Schumann G, Zoller B, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26(5):537–547.
    1. Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT) Cephalalgia. 2010;30(11):1336–1345.
    1. Edgar online, excerpt from a 10-K SEC Filing 2003. Available from: . Accessed 27 Oct 2014.
    1. Center for Drug Evaluation and Research CR. Zipsor (diclofenac potassium soft gelatin capsules) NDA 22-202 2007. Available from: .
    1. Zuniga JR, Phillips CL, Shugars D, Lyon JA, Peroutka SJ, Swarbrick J, et al. Analgesic safety and efficacy of diclofenac sodium softgels on postoperative third molar extraction pain. J Oral Maxillofac Surg. 2004;62(7):806–815.
    1. Hersh EV, Levin LM, Adamson D, Christensen S, Kiersch TA, Noveck R, et al. Dose-ranging analgesic study of Prosorb diclofenac potassium in postsurgical dental pain. Clin Ther. 2004;26(8):1215–1227.
    1. Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, et al. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther. 2009;31(10):2072–2085.
    1. Daniels SE, Baum DR, Clark F, Golf MH, McDonnell ME, Boesing SE. Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain. Curr Med Res Opin. 2010;26(10):2375–2384.
    1. Cordero JA, Alarcon L, Escribano E, Obach R, Domenech J. A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci. 1997;86(4):503–508.
    1. Cordero JA, Camacho M, Obach R, Domenech J, Vila L. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm. 2001;51(2):135–142.
    1. Barkin RL. Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome. Am J Ther. 2001
    1. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord. 2004;19(5):28.
    1. Surgeons AAoO. Treatment of osteoarthritis of the knee. Evidence-based guideline 2nd edition 2013. Available from: . Accessed 6 Aug 2014.
    1. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465–474.
    1. (AAOS) AAoOS. Treatment of osteoarthritis of the knee (non-arthroplasty). Rosemont: 2008. Available from: .
    1. Stanos S. Osteoarthritis guidelines: a progressive role for topical NSAIDs. J Am Osteopath Assoc. 2013;113(2):123–127.
    1. Brunner M, Dehghanyar P, Seigfried B, Martin W, Menke G, Muller M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol. 2005;60(5):573–577.
    1. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000;60(3):555–574.
    1. Barthel HR, Haselwood D, Longley S, 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203–212.
    1. Baraf HS, Gloth FM, Barthel HR, Gold MS, Altman RD. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs Aging. 2011;28(1):27–40.
    1. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886] BMC Musculoskelet Disord. 2005;6:44.
    1. Roth SH, Shainhouse J. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: A randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017–2023.
    1. Fuller P, Roth S. Diclofenac sodium topical solution with dimethyl sulfoxide, a viable alternative to oral nonsteroidal anti-inflammatories in osteoarthritis: review of current evidence. J Multidiscip Healthc. 2011;4:223–231.
    1. Shainhouse JZ, Grierson LM, Naseer Z. A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. 2010;17(6):566–576.
    1. Simon LS, Grierson LM, Naseer Z, Bookman AA. Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238–245.
    1. Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(9):1991–1999.
    1. Fini A, Fazio G, Gonzalez-Rodriguez M, Cavallari C, Passerini N, Rodriguez L. Formation of ion-pairs in aqueous solutions of diclofenac salts. Int J Pharm. 1999;187(2):163–173.
    1. Kuehl K, Carr W, Yanchick J, Magelli M, Rovati S. Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3 % (DETP) in minor soft tissue injury. Int J Sports Med. 2011;32(8):635–643.
    1. McCarberg BH, Argoff CE. Topical diclofenac epolamine patch 1.3 % for treatment of acute pain caused by soft tissue injury. Int J Clin Pract. 2010;64(11):1546–1553.
    1. Lionberger DR, Joussellin E, Yanchick J, Magelli M, Lanzarotti A. Pooled analysis of clinical trial data evaluating the safety and effectiveness of diclofenac epolamine topical patch 1.3 % for the treatment of acute ankle sprain. Open Access. J Sports Med. 2011;2:75–84.
    1. Summary of Product Characteristics—Voltarol Ampoules. Camberly: Novartis Pharmaceuticals UK Ltd.; 2014 [updated January 22, 2014; cited 2015 March 23]. Available from: .
    1. New Zealand Data Sheet: Voltaren. Auckland: Novartis New Zealand Limited; [cited 2015 March 24]. Available from: .
    1. Mermelstein F, Hamilton DA, Wright C, Lacouture PG, Ramaiya A, Carr DB. Single-dose and multiple-dose pharmacokinetics and dose proportionality of intravenous and intramuscular HPβCD-diclofenac (Dyloject) compared with other diclofenac formulations. Pharmacotherapy. 2013;33(10):1012–1021.
    1. Christensen K, Daniels S, Bandy D, Ernst CC, Hamilton DA, Mermelstein FH, et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia progress. 2011;58(2):73–81.
    1. Leeson RM, Harrison S, Ernst CC, Hamilton DA, Mermelstein FH, Gawarecki DG, et al. Dyloject, a novel injectable diclofenac formulation, offers greater safety and efficacy than Voltarol for postoperative dental pain. Reg Anesth Pain Med. 2007;32(4):303–310.
    1. Daniels S, Melson T, Hamilton DA, Lang E, Carr DB. Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple-dose trial. Clin J Pain. 2013;29(8):655–663.
    1. Guhmann M, Thommes M, Gerber F, Pollinger N, Klein S, Breitkreutz J, et al. Design of biorelevant test setups for the prediction of diclofenac in vivo features after oral administration. Pharm Res. 2013;30(6):1483–1501.
    1. Murphy LM, Matthews GP. US Patent 5,256,699 dispersible tablet formulation of diclofenac acid free base 1993. Available from: . Accessed 27 March 2014.
    1. Low dose diclofenac (Zorvolex) for pain. Med Lett. 2014;56(1437):19–20.
    1. Food and Drug Administration. Public health advisory—FDA announces important changes and additional warnings for cox-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) 2005. Available from: . Accessed 13 Mar 2014.
    1. Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013;125(5):130–138.
    1. Gibofsky A, Hochberg MC, Jaros M, Young CL. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12-week, phase 3 study. Curr Med Res Opin. 2014;22:1–29.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa